GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 1, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK bought back some of its own stock on April 1st.
AI Summary
On April 1, 2025, GSK plc announced through its corporate stockbroker, Citigroup Global Markets Limited, that it purchased a certain number of its own ordinary shares. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or strategic information.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- April 1, 2025 (date) — Date of purchase
FAQ
What was the specific number of GSK plc ordinary shares purchased on April 1, 2025?
The filing states that GSK plc purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity.
What was the total dollar amount spent by GSK plc on share repurchases on April 1, 2025?
The filing does not disclose the total dollar amount of the share repurchases made on April 1, 2025.
Who acted as GSK plc's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as GSK plc's corporate stockbroker for the transaction.
What is the nominal value of GSK plc's ordinary shares mentioned in the filing?
The filing mentions GSK plc's ordinary shares are of 31¼ pence each.
Is GSK plc filing an annual report on Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 1, 2025 regarding GSK plc (GLAXF).